undamentalytics Newsletter

Sayer Kevin R: insider trades

Chief executive, Officer at Dexcom. No open-market purchases and 16 sales not made under a pre-set plan, reported from June 6, 2012 to March 14, 2025.

What happened after Sayer Kevin R’s sales?

After their sales, the shares moved +14.2% against the index over 12 months on average (a negative figure means selling was the right call); 50% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Sayer Kevin R: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 16 +12.0% +7.8% 31% 11 2.15 0.058 No reliable evidence
Sales, 12 months after the report 16 +14.2% −0.9% 50% 11 0.94 0.37 No reliable evidence
Sales, 12 months after the trade 16 +13.7% −3.6% 56% 11 0.91 0.39 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Dexcom DXCM Chairman, CEO & President016June 6, 2012March 14, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
March 14, 2025March 12, 2025 DXCM Sale $2,287,209 +9.7%−23.2%−29.1%
January 30, 2025January 29, 2025 DXCM Sale $2,899,231 −0.5%−33.4%−31.8%
January 17, 2024January 16, 2024 DXCM Sale $4,614,490 +0.2%−60.5%−58.0%
January 24, 2023January 20, 2023 DXCM Sale $4,822,940 +18.7%−6.3%−6.5%
September 13, 2021September 9, 2021 DXCM Sale $1,633,280 −4.0%−23.3%−24.6%
March 12, 2021March 10, 2021 DXCM Sale $5,096,848 +5.4%+5.9%+4.5%
September 11, 2020September 9, 2020 DXCM Sale $3,969,060 −20.3%+4.6%+3.5%
March 13, 2020March 11, 2020 DXCM Sale $5,395,507 +68.3%+7.2%−0.8%
September 11, 2019September 9, 2019 DXCM Sale $2,146,256 +39.5%+147.5%+153.8%
May 10, 2018May 9, 2018 DXCM Sale $1,454,961 +37.9%+32.7%+31.1%
August 11, 2016August 9, 2016 DXCM Sale $1,819,600 −30.7%−36.0%−37.1%
August 18, 2015August 14, 2015 DXCM Sale $3,409,350 −12.3%−12.2%−14.3%
May 6, 2015May 4, 2015 DXCM Sale $1,700,250 +38.0%−9.7%−7.1%
December 16, 2014December 12, 2014 DXCM Sale $539,700 +5.9%+43.1%+51.6%
August 15, 2014August 11, 2014 DXCM Sale $876,400 +14.8%+109.2%+108.9%
June 6, 2012June 4, 2012 DXCM Sale $128,982 +21.6%+81.1%+75.1%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Sayer Kevin R traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.